TheraCryf

Switzerland's STALICLA SA has bagged the rights to Novartis AG 's mavoglurant, which has had a complicated clinical development history, with the initial aim of putting the drug into late-stage tri

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Terray Inks Initial Partnership With Ca